FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

Introduction The U.S. Food and Drug Administration (FDA) has granted approval for Sanofi’s (NASDAQ:SNY) hemophilia therapy, Qfitlia, marking a significant advancement in treatment options for patients ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

However, on March 16, NBC News released results of a national poll that show a 47% approval rating for Trump and a 51% disapproval rating. Furthermore, regarding Trump's early job performance on ...

In a White House press release Monday, the administration shared with other news sources the same poll results, citing “Trump ties for highest approval he’s ever had — as more Americans say ...

The EMEA s approval permits EVICEL to be marketed ... Safe Harbor Statement This news release contains forward-looking statements. Forward-looking statements provide the Company's current ...

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the ...